NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $16.80 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$16.89 +0.09 (+0.51%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sarepta Therapeutics Stock (NASDAQ:SRPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sarepta Therapeutics alerts:Sign Up Key Stats Today's Range$16.76▼$17.2150-Day Range$16.40▼$23.7752-Week Range$10.41▼$43.92Volume1.96 million shsAverage Volume2.98 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$27.17Consensus RatingHold Company Overview Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities. Sarepta’s commercial products include several exon-skipping therapies approved by the U.S. Food and Drug Administration for specific DMD mutations. Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen) use chemically modified oligonucleotides to induce exon skipping and restore production of functional dystrophin protein. In addition, Elevidys (delandistrogene moxeparvovec) is an adeno-associated virus (AAV)-based gene therapy designed to deliver a shortened dystrophin gene to muscle tissue, representing one of the first approved gene therapies for DMD. Founded in the late 1980s under the name AVI BioPharma and rebranded as Sarepta Therapeutics in 2012, the company initially explored antiviral technologies before pivoting to neuromuscular disease in 2010. Sarepta now maintains commercial operations across North America and has established collaborations in Europe and Asia to support clinical trials and regulatory filings. The company continues to expand its pipeline, exploring next-generation gene editing, microdystrophin constructs and treatments for other genetic muscle disorders such as limb-girdle muscular dystrophy. Leadership at Sarepta is spearheaded by President and Chief Executive Officer Douglas Ingram, who joined the company in 2018 and assumed the CEO role in 2021. Under his guidance, Sarepta has grown from a single-product organization into a multi-asset innovator with a broad platform in precision genetic medicine. The company’s executive team combines expertise in neurology, genetic engineering and regulatory affairs to advance therapies from early-stage research through global commercialization.AI Generated. May Contain Errors. Read More Sarepta Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreSRPT MarketRank™: Sarepta Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 234th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingSarepta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on no strong buy ratings, 9 buy ratings, 13 hold ratings, and 6 sell ratings.Upside PotentialSarepta Therapeutics has a consensus price target of $27.17, representing about 61.7% upside from its current price of $16.80.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-37.94% Earnings GrowthEarnings for Sarepta Therapeutics are expected to decrease by -37.94% in the coming year, from $3.69 to $2.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -17.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -17.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioSarepta Therapeutics has a PEG Ratio of 0.19. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.35% of the float of Sarepta Therapeutics has been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 9.54.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 1.64%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentSarepta Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sarepta Therapeutics this week, compared to 12 articles on an average week.Search Interest40 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 471% compared to the previous 30 days.MarketBeat Follows13 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123,208.00 in company stock.Percentage Held by Insiders6.90% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRPT Stock News HeadlinesKROS Stock Guide to Rinvatercept in DMD and ALS for 2026May 22 at 2:06 PM | finance.yahoo.comShould You Buy KROS After Q1 Miss and Takeda Deal Reset?May 22 at 2:06 PM | finance.yahoo.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 25 at 1:00 AM | Paradigm Press (Ad)KROS Turns to Next Wave of TGF-Beta Muscle TherapiesMay 22 at 2:06 PM | finance.yahoo.comWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20, 2026 | finance.yahoo.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19, 2026 | proactiveinvestors.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX)May 17, 2026 | theglobeandmail.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by BrokeragesMay 16, 2026 | americanbankingnews.comSee More Headlines SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $21.52 on January 1st, 2026. Since then, SRPT shares have decreased by 21.9% and is now trading at $16.80. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported $3.16 earnings per share for the quarter, beating the consensus estimate of $0.98 by $2.18. The business's revenue was down 1.9% on a year-over-year basis. Read the conference call transcript. Does Sarepta Therapeutics have any subsidiaries? Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' top institutional investors include First Trust Advisors LP (3.92%), Bank of America Corp DE (2.03%), Renaissance Technologies LLC (1.58%) and Bank of New York Mellon Corp (0.65%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Ian Michael Estepan, Richard Barry, Claude Nicaise, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Kathryn Jean Boor and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN). Company Calendar Last Earnings5/06/2026Today5/25/2026AGM 20266/04/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 10 days, SRPT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,372Year Founded1980Price Target and Rating Average Price Target for Sarepta Therapeutics$27.17 High Price Target$80.00 Low Price Target$13.00 Potential Upside/Downside+61.7%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage28 Analysts Profitability EPS (Trailing Twelve Months)($0.96) Trailing P/E RatioN/A Forward P/E Ratio4.55 P/E Growth0.19Net Income-$713.41 million Net Margins-2.94% Pretax Margin1.12% Return on Equity7.56% Return on Assets2.94% Debt Debt-to-Equity Ratio0.56 Current Ratio4.63 Quick Ratio2.62 Sales & Book Value Annual Sales$2.18 billion Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value$14.26 per share Price / Book1.18Miscellaneous Outstanding Shares105,576,000Free Float98,291,000Market Cap$1.77 billion OptionableOptionable Beta0.26 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:SRPT) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
